Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287332 · ClinicalTrials.gov registry record · NA
BLOOM: Pragmatic Feasibility Trial
A NA study of Sepsis and Infection, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT07287332: Recruiting NA study of Sepsis and Infection, sponsored by Mayo Clinic.
NCT07287332 is a NA study of Sepsis and Infection that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287332, a NA study of Sepsis and Infection, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.
Primary Outcome
Number of patients who quality for the study out of total number of patients screened, reported as a percentage
Interventions
- OTHER Usual Care
- OTHER Up-front individualized dosing algorithm
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT07287332 shows while recruiting
NCT07287332 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT07287332 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07287332 about?
NCT07287332 is a clinical study titled "BLOOM: Pragmatic Feasibility Trial". The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more i...
What is the current status of trial NCT07287332?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2026-01-15. Estimated completion is 2027-07.
What conditions does trial NCT07287332 study?
This clinical trial studies the following conditions: Sepsis, Infection.
What interventions are being tested in trial NCT07287332?
The interventions under investigation include: Usual Care (OTHER), Up-front individualized dosing algorithm (OTHER).
Who is sponsoring clinical trial NCT07287332?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287332 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07287332's enrollment target sits among peer trials
300 34th of 90 higher than 54 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
RECRUITING · NA
-
Evaluation of Pediatric eCART Implementation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI